Drug Trial Radar · NCT05772169
Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)
Last checked: Nov 20, 2026Latest source record: Jan 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,113
Actual
Start
Mar 31, 2023
Primary completion
Nov 19, 2024
Study completion Dec 18, 2024
Sponsor
- Lead sponsor
- Corcept TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Mar 16, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 4 study with 2 parts: Part 1 (Prevalence Phase) is non-interventional and will assess the prevalence of hypercortisolism in a population with difficult to control type 2 diabetes (T2D) (hemoglobin A1c ≥7.5%) despite receiving standard-of-care therapies. Part 2 (Treatment Phase) is a randomized, prospective, placebo-controlled, double-blind multi-center trial that will assess the safety and efficacy of mifepristone treatment in patients with hypercortisolism who have difficult to control T2D despite receiving standard of care therapies.
Conditions
- Hypercortisolism
- Diabetes Mellitus, Type 2
Interventions
Mifepristone 300 MG [Korlym]Drug
Mifepristone tablets for once daily oral dosing
Placebo for mifepristoneDrug
Placebo tablets for once daily oral dosing
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 Prevalence Phase: Prevalence of HypercortisolismTime frame: Screening
- Part 2 Treatment Phase: Effect of Treatment on Hypercortisolism with Abnormal Adrenal CT ScanTime frame: Baseline Day 1 to week 24
- Part 2 Treatment Phase: Effect of Treatment on Hypercortisolism without Abnormal Adrenal CT ScanTime frame: Baseline Day 1 to week 24
Locations
36 sites in 1 country. Site status is shown where the registry gives one.
Site 407
Escondido, California
Site 379
Gardena, California
Site 378
Huntington Park, California
Site 406
La Jolla, California
Site 373
Los Angeles, California
Site 387
Tarzana, California
Site 375
Torrance, California
Site 444
Edgewater, Florida
Site 015
Fort Lauderdale, Florida
Site 009
Atlanta, Georgia
Site 097
Atlanta, Georgia
Site 046
Covington, Kentucky
Site 061
Metairie, Louisiana
Site 377
New Orleans, Louisiana
Site 205
New Orleans, Louisiana
Site 410
Baltimore, Maryland
Site 394
Hyattsville, Maryland
Site 067
Boston, Massachusetts
Site 074
Ann Arbor, Michigan
Site 371
Las Vegas, Nevada
Site 070
Albany, New York
Site 411
Smithtown, New York
Site 181
Chapel Hill, North Carolina
Site 059
Wilmington, North Carolina
Site 436
Cincinnati, Ohio
Site 042
Cleveland, Ohio
Site 077
Columbus, Ohio
Site 195
Columbus, Ohio
Site 435
Grants Pass, Oregon
Site 049
Portland, Oregon
Site 456
Cedar Park, Texas
Site 370
Dallas, Texas
Site 408
Lufkin, Texas
Site 054
San Antonio, Texas
Site 369
San Antonio, Texas
Site 405
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.